Clinical Trial

Halt Aging in Survivors of Blood Cancers

Study acronym: HALTAging-1

Recruiting

Summary

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Protocol Amendment History 4 changes

critical Phase changed: Phase 2 -> not applicable 2026-07-02

critical Recruitment opened 2026-05-19

notable Primary completion pushed: 2031-08-01 -> 2032-03-25 2026-05-19

minor Completion pushed: 2032-03-01 -> 2033-03-25 2026-05-19

Trial Details

NCT Number	NCT07292272
Lead Sponsor	University of Nebraska
Conditions	Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition
Enrollment	180 participants
Start Date	2026-04-09
Primary Completion	2032-03-25 (estimated)
Study Completion	2033-03-25 (estimated)
Updated on ClinicalTrials.gov	2026-07-01